NCIMMUNE LEADING EARLY CANCER DETECTION

Early detection may be your best chance for surviving lung cancer.

The Facts:

  • Worldwide, nearly 1.83 million new cases of lung cancer were estimated to have been diagnosed in 2012, with incidence rates varying across the world.1
  • Lung cancer is the most common cause of cancer death worldwide, with around 1,590,000 deaths from lung cancer in 2012 (19% of the total).
  • The 5-year survival rate is only 18%2
  • Almost 80% of lung cancer is diagnosed after spread to other organs2
  • 52% of patients perish in the 1st year after diagnosis2
  • If still localized, the 5-year survival rate for lung cancer more than triples to 56%.2

As reported in the landmark US National Lung Cancer Screening Trial (NLST) published in the New England Journal of Medicine in July 2011, early detection enabled by low-dose CT scans resulted in a 20% reduction in lung cancer mortality.3

Annual low-dose CT scanning (LDCT) is now an approved method of lung cancer screening in the US with associated reimbursement. BUT only if you meet the strict criteria published by the U.S. Preventive Services Task Force (USPSTF) guidelines4, derived from the National Lung Screening Trial (NLST): age 55-80, current or ex smoker (cessation within 15 years) and 30 pack year smoking history.

As a simple blood test, EarlyCDT-Lung can be used when a patient is at increased risk of lung cancer but does not meet the criteria for annual CT screening, or for those patients who are unwilling or unable to commit to annual CT scanning.

1 Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer, Accessed July 2017.
2 Howlader N, et al. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data sub
3 The National Lung Screening Trial Research Team.  N Engl J Med 2011; 365:395-409.
4 Final Update Summary: Lung Cancer: Screening. U.S. Preventive Services Task Force. July 2015. https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/lung-cancer-screening

How common is lung cancer in the USA?1

  • Lung cancer remains the number one cancer killer in the USA
  • An estimated 155,870 people will die of lung cancer in the US in 2017
  • Over 220,000 new cases of lung cancer diagnosed annually in the US
  • Approximately 36.5 million smokers in the US

1 Howlader N, et al. SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data sub

How common is lung cancer in Europe and the UK?

  • In 2013, 269,000 people died from lung cancer in the EU-28, which represents 21% of all cancer deaths.1
  • 46,403 new cases of lung cancer in the UK in 20142
  • 35,895 deaths from lung cancer in the UK in 20142
  • 13% of total cancer cases in the UK were lung cancer in 20142

1 Eurostat Statistics Explained. Cancer statistics – specific cancers. http://ec.europa.eu/eurostat/statistics-explained/index.php/Cancer_statistics_-_specific_cancers#Lung_cancer, Accessed July 2017.
2 Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer, Accessed July 2017.

How common is lung cancer in Asia?1

  • 51 percent of the world’s lung cancer cases occur in Asia
  • 21 percent of cancer deaths in Asia are due to lung cancer
  • China is the largest consumer of tobacco in the world with about 301 million current smokers
  • About two-thirds of young Chinese men smoke, and estimates indicate half of them will die as a result of smoking if they don’t quit
  • Smoking deaths in China are estimated to be around 2 million in 2030 and are expected to triple by 2050 to 3 million people a year – more than the population of Chicago

International Association for the Study of Lung Cancer. Lung Cancer Fact Sheet – 2016 – Asia. https://www.iaslc.org/lung-cancer-fact-sheet-2016-asia, Accessed July 2017.

PLEASE READ THE FOLLOWING STATEMENT CAREFULLY

Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept